This study is testing a treatment called OPB-101 for women with ovarian cancer that has returned and is resistant to platinum-based chemotherapy. OPB-101 is a type of CAR T cell therapy, which means your own immune cells (T cells) are specially modified in a lab to fight cancer. The main goals are to see if OPB-101 is safe and to find the best dose. You would need to be at least 18 years old and have a specific type of ovarian, peritoneal, or fallopian tube cancer that has come back within 6 months of your last platinum treatment. After your T cells are modified, they will be given back to you as a one-time treatment, and you will stay in the hospital for this. Researchers will then check on you frequently for the first few months to monitor your safety.

Study design

This is an interventional study with a planned enrollment of 30 participants. It is a Phase 1a/b study, which means it's an early-stage trial looking at safety and dosage.

What's involved

You will have your T cells modified and then receive OPB-101 as a one-time treatment in the hospital. You will then have frequent check-ups at the clinical site for the first few months.

Compensation

Not stated in the trial record.

Follow-up

Your safety will be monitored for up to 2 years after receiving the treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.